PEPFAR — President's Emergency Plan for AIDS Relief

The President's Emergency Plan for AIDS Relief (PEPFAR), authorized under the United States Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act of 2003 (22 U.S.C. §§ 7601–7682), is the largest commitment by any nation to address a single disease in history. For the broader foreign assistance framework through which PEPFAR is implemented, see Foreign Assistance Act and USAID. For the domestic HIV/AIDS program that provides care to Americans living with HIV, see Ryan White HIV/AIDS program. Launched by President George W. Bush in 2003 and bipartisanly reauthorized multiple times, PEPFAR has provided over $110 billion in HIV/AIDS treatment, prevention, and care in more than 50 countries, primarily in sub-Saharan Africa. As of 2024, PEPFAR-supported programs provide antiretroviral treatment (ART) to approximately 20.6 million people and have prevented an estimated 25 million deaths. PEPFAR is administered primarily through the State Department's Office of the Global AIDS Coordinator (OGAC) and implemented through USAID, CDC, NIH, DOD, and Peace Corps. The program has been the centerpiece of U.S. global health leadership for two decades — and in 2025–2026, it became a major target of the Trump administration's DOGE-driven foreign aid cuts, with funding freezes and reauthorization delays threatening to disrupt treatment for millions of people who depend on PEPFAR-funded antiretrovirals for survival.

Current Law (2026)

Legal Authority

• 22 U.S.C. § 7601 — Congressional findings: Congress found that HIV/AIDS is a catastrophic epidemic requiring urgent emergency response; the U.S. has a moral and strategic interest in responding; developing countries lack capacity to address the epidemic without international assistance; the program is explicitly framed as both humanitarian and national security policy
• 22 U.S.C. § 7602 — Definitions: defines "AIDS," "HIV," "eligible country," "partner government," and the programmatic hierarchy of "treatment," "prevention," "palliative care," and "orphan and vulnerable children" programs
• 22 U.S.C. § 7611 — Annual report: the President must submit an annual report to Congress on PEPFAR implementation, covering the number of individuals receiving ART, prevention services, and care, along with financial accountability reporting
• 22 U.S.C. § 7621 — Procurement flexibility: PEPFAR may procure antiretroviral drugs (ARVs) through U.S. or foreign manufacturers; the original statute required U.S.-manufactured branded drugs, but subsequent amendments authorized generic ARV procurement (dramatically reducing per-patient costs from ~$1,000/year for branded to ~$100–150/year for generics)
• 22 U.S.C. § 7631 — Prevention programs: PEPFAR funds comprehensive HIV prevention programs including ABC (Abstinence, Be faithful, use Condoms) — the ABC requirement has been politically contested; the Biden administration removed the requirement for a fixed percentage of prevention funding to go to abstinence programs; the Trump administration has re-emphasized abstinence/fidelity components
• 22 U.S.C. § 7671 — Civil society organizations: PEPFAR must work with and fund local civil society organizations, faith-based organizations, and community groups; a substantial share of PEPFAR funding goes directly to local organizations rather than through large international NGOs

How It Works

PEPFAR's central mechanism is antiretroviral therapy (ART) at population scale: in 2003, fewer than 50,000 people in sub-Saharan Africa were receiving treatment; today PEPFAR supports over 20 million on ART. ART suppresses HIV viral load to undetectable levels — preventing AIDS-related death and making individuals effectively non-transmissible — and the cost has dropped from roughly $10,000 per patient per year in 2003 (branded drugs) to approximately $100–150 (generic ARVs in 2024), which made sustained mass treatment financially feasible. PEPFAR works through U.S. implementing agencies (CDC provides technical assistance, USAID funds NGOs) partnered with host-country health ministries rather than building parallel U.S.-run systems. The DREAMS program (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe) reflects a prevention layer that ART alone can't provide: it targets adolescent girls and young women in 15 high-burden African countries — the demographic with the highest new-infection rates — through a combined package of HIV testing, ARVs, school support, social protection, and violence prevention services. Funding and accountability flow through Country Operational Plans (COPs) — annual planning documents negotiated between the Office of the Global AIDS Coordinator (OGAC), partner governments, and in-country implementing partners — that specify treatment, testing, and prevention targets for each country. PEPFAR appropriations run through the State Department's Global Health Programs account and are subject to GAO review, independent evaluation by the Global AIDS Coordinator, and Congressional oversight that has made reauthorization debates among the most closely watched in global health policy.

How It Affects You

If you work in global health, infectious disease research, or international development: PEPFAR is the largest source of HIV/AIDS program funding in the world — it funds the majority of HIV treatment programs, laboratory infrastructure, health worker training, and data systems in sub-Saharan Africa. The 2025–2026 funding freeze and DOGE-driven cuts have disrupted program operations at implementing partners globally; clinics that ran on PEPFAR funding have stopped operations, patients have missed ARV doses, and supply chains have been disrupted. The immediate consequence of treatment interruption is viral rebound, drug resistance, and mortality. Monitor OGAC's country operational plan updates and Kaiser Family Foundation's PEPFAR tracker (kff.org) for current program status.

If you are a taxpayer and U.S. citizen evaluating foreign aid: PEPFAR represents less than 0.2% of the U.S. federal budget. The economic return on PEPFAR is substantial: healthy workers in PEPFAR partner countries produce goods and services that support U.S. export markets; U.S. pharmaceutical and health companies receive significant revenue from PEPFAR procurement; preventing AIDS deaths reduces costs to humanitarian assistance programs that would otherwise support AIDS orphans and affected communities. The bipartisan consensus that PEPFAR represents the most efficient U.S. aid program — with independently verified treatment targets and per-patient costs — reflects this cost-effectiveness record.

If you are a pharmaceutical or medical supply company: PEPFAR is a significant procurement market. Generic ARV manufacturers (primarily Indian firms like Cipla, Aurobindo, and Mylan-Viatris) supply the majority of PEPFAR-funded drugs. U.S. firms supply branded products for specific regimens. Diagnostic equipment (viral load machines, rapid tests), laboratory reagents, and health information systems represent additional procurement categories. OGAC's PEPFAR Supply Chain program and the USAID Global Health Supply Chain program manage procurement.

If you are affected by or concerned about global health security: HIV/AIDS remains the leading infectious disease killer globally. Untreated HIV accelerates susceptibility to TB (the world's leading infectious disease killer), contributing to drug-resistant TB spread. PEPFAR-funded programs directly reduce the pool of untreated HIV that drives drug resistance and enables opportunistic infections. A collapse of PEPFAR would generate a global health crisis with potential spillover into new infections in countries where PEPFAR-funded prevention has suppressed transmission.

State Variations

PEPFAR is exclusively federal foreign assistance. No state variations.

Implementing Regulations

• PEPFAR is implemented through USAID and State Department procurement regulations (AIDAR — AID Acquisition Regulation, 48 CFR Chapter 7); grants and contracts with implementing partners are governed by 2 CFR Part 200 (Uniform Guidance)
• Country Operational Plans (COPs) are the primary implementation documents; published at pepfar.gov

Pending Legislation

• PEPFAR Reauthorization — The most recent reauthorization expired; the 119th Congress has debated reauthorization with significant controversy over abortion policy riders and program funding levels; the Trump administration's 90-day foreign assistance review (January 2025) paused PEPFAR disbursements pending review; restoration has been partial and contested
• Global Health Security Act — Proposals to integrate PEPFAR with broader global health security programs

Recent Developments

• The Trump administration's January 2025 executive order pausing all foreign assistance for 90-day review immediately disrupted PEPFAR program operations; a federal court issued a preliminary injunction ordering restoration of PEPFAR funding, but implementation was incomplete and contested
• DOGE has targeted PEPFAR as part of broader USAID restructuring; the administration has argued that PEPFAR should be restructured to focus more narrowly on treatment and less on prevention and civil society strengthening
• Congressional Republicans who historically supported PEPFAR reauthorization have faced internal pressure from fiscal conservatives; the program's bipartisan coalition has frayed
• WHO and UNAIDS have warned that treatment interruptions resulting from funding freezes could generate drug-resistant HIV strains that would be harder and more expensive to treat globally, including affecting U.S. residents
• As of April 2026, PEPFAR funding remains partially frozen pending reauthorization; implementing partners have drawn down reserves and laid off staff; the long-term program status is uncertain